GlassScriptPhysician profile
Emmanuel R Reyes
NPI 1174592521
$11,276.87
in general payments reported to CMS, 2019-2025
31 companies · $2,357 in 2025
The $2,357 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,444 · 2020: $1,041 · 2021: $1,289 · 2022: $1,701 · 2023: $1,740 · 2024: $1,705 · 2025: $2,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,723 · Education: $58.77 · Long Term Medical Supply Or Device Loan: $19.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,722.79 |
| Education | $58.77 |
| Long Term Medical Supply Or Device Loan | $19.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,932.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,462.30 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Lilly USA, LLC | $1,178.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,177.16 | 2019-2025 | Evenity, Repatha, Repatha |
| Abbott Laboratories | $1,011.44 | 2021-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $664.54 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $511.82 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $494.42 | 2019-2025 | Capvaxive |
| Sanofi-Aventis U.S. LLC | $365.92 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $318.42 | 2019-2024 | Livalo, Zoryve |
| Mannkind Corporation | $291.79 | 2019-2025 | Afrezza |
| Exact Sciences Corporation | $276.18 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $272.15 | 2019-2023 | Cycloset |
| Boston Scientific Corporation | $243.92 | 2021-2022 | |
| Amarin Pharma, INC. | $208.41 | 2019-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $158.68 | 2021-2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $113.60 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Philips North America LLC | $107.23 | 2022 | |
| Allergan, INC. | $102.50 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $86.13 | 2021-2023 | Jynarque |
| Azurity Pharmaceuticals, INC. | $52.37 | 2023 | Edarbi |
| Corcept Therapeutics | $48.28 | 2024-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $45.84 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $36.51 | 2022 | |
| Pfizer INC. | $24.24 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $21.44 | 2022 | |
| Sanofi Pasteur INC. | $16.51 | 2023 | |
| Althera Pharmaceuticals LLC | $15.66 | 2022 | |
| Horizon Therapeutics Plc | $14.66 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.00 | 2021 | |
| Hikma Pharmaceuticals USA | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.